Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.270
-0.070 (-5.22%)
At close: Apr 1, 2025, 4:00 PM
1.261
-0.009 (-0.73%)
After-hours: Apr 1, 2025, 4:02 PM EDT
SONN Revenue
Sonnet BioTherapeutics Holdings had revenue of $1.00M in the quarter ending December 31, 2024, with 5,268.84% growth. This brings the company's revenue in the last twelve months to $1.00M, up 674.14% year-over-year. In the fiscal year ending September 30, 2024, Sonnet BioTherapeutics Holdings had annual revenue of $18.63K, down -87.40%.
Revenue (ttm)
$1.00M
Revenue Growth
+674.14%
P/S Ratio
1.40
Revenue / Employee
$76,923
Employees
13
Market Cap
3.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SONN News
- 9 hours ago - Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewsWire
- 6 days ago - Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas - GlobeNewsWire
- 13 days ago - Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - GlobeNewsWire
- 21 days ago - Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - GlobeNewsWire
- 5 weeks ago - Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewsWire